David J Stewart
Overview
Explore the profile of David J Stewart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
146
Citations
3982
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mittal A, Moore S, Navani V, Jiang D, Stewart D, Liu G, et al.
Curr Oncol
. 2024 Jul;
31(7):3738-3751.
PMID: 39057147
Evidence from phase three clinical trials helps shape clinical practice. However, a very small minority of patients with cancer participate in clinical trials and many trials are not completed on...
2.
3.
4.
Rawson N, Stewart D
Clinicoecon Outcomes Res
. 2024 May;
16:437-445.
PMID: 38812711
Purpose: To evaluate whether time targets for Canadian Agency for Drugs and Technologies in Health (CADTH) reimbursement reviews and pan-Canadian Pharmaceutical Alliance (pCPA) price negotiations are being achieved for oncology...
5.
Stewart D, Bradford J, Sehdev S, Ramsay T, Navani V, Rawson N, et al.
Curr Oncol
. 2024 May;
31(5):2453-2480.
PMID: 38785465
Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation. Burdensome...
6.
Sehdev S, Rawson N, Aseyev O, Buick C, Butler M, Edwards S, et al.
Curr Oncol
. 2024 Apr;
31(4):1803-1816.
PMID: 38668039
Patient access to new oncology drugs in Canada is only possible after navigating multiple sequential systemic checkpoints for national regulatory approval, health technology assessment (HTA) and collective government price negotiation....
7.
Nasser A, de Zwart B, Stewart D, Zielke A, Blazek K, Heywood A, et al.
Aust Crit Care
. 2024 Apr;
37(5):686-693.
PMID: 38584063
Background: Patients admitted from the emergency department to the wards, who progress to a critically unwell state, may require expeditious admission to the intensive care unit. It can be argued...
8.
Stewart D, Cole K, Bosse D, Brule S, Fergusson D, Ramsay T
Curr Oncol
. 2024 Mar;
31(3):1600-1617.
PMID: 38534955
Using digitized data from progression-free survival (PFS) and overall survival Kaplan-Meier curves, one can assess population survival kinetics through exponential decay nonlinear regression analyses. To demonstrate their utility, we analyzed...
9.
Stewart D, Ramsay T, Navani V, Liu G, Jiang D, Batist G
J Clin Oncol
. 2024 Jan;
42(8):973-974.
PMID: 38290085
No abstract available.
10.
Farah E, Kenney M, Kica A, Haddad P, Stewart D, Bradford J
Curr Oncol
. 2023 Sep;
30(9):8310-8327.
PMID: 37754518
Historically, subject matter experts and healthcare professionals have played a pivotal role in driving oncology clinical trials. Although patients have been key participants, their deliberate and active contribution to the...